



# Public Declaration of Interests and Confidentiality Undertaking of European Medicines Agency (EMA)

## SCIENTIFIC COMMITTEE MEMBERS AND EXPERTS

### I, Maurizio Volterrani

Organisation/Company:

Country:

Declare on my honour that, to the best of my knowledge, the only direct or indirect interests I have in the pharmaceutical industry are those listed below:

#### 1.1 Employment

No interest declared

#### 1.2 Consultancy

No interest declared

#### 1.3 Strategic advisory role

Time Period	Start Date	End Date	Name of pharmaceutical company	Type	Product name	Therapeutic indication	General role / Area of activity
Past	01-11-2013	01-09-2017	NOVARTIS Farma	Individual product related	RLX 030 Seralaxine	Acute Heart Failure	null

#### 1.4 Financial interests

No interest declared

#### 1.5 Principal investigator

Time Period	Start Date	End Date	Name of pharmaceutical company	Product Name	Therapeutic indication
Past	01-12-2013	01-06-2020	Institute de Recherches Internationales Servier	Trimetazidine	Angina Pectoris

#### 1.6 Investigator

Time Period	Start Date	End Date	Name of pharmaceutical company	Product Name	Therapeutic indication
Past	01-10-2020	01-10-2021	VIFOR	Patiromer RLY5016	hyperkalemia and heart failure
Current	01-06-2021	22-03-2023	Astra Zeneca	AZD9977 and dapagliflozin	Heart failure and LVEF >55%

Current	01-11-2021	22-03-2023	Merck	Vericiguat	Heart Failure
Current	01-10-2022	22-03-2023	AstraZeneca	SZC (Lokelma)	Hyperkalemia
Current	01-09-2020	22-03-2023	AMGEN	Omecantiv Mecarbil AMG 423	heart failure and exercise capacity
Past	01-09-2020	01-10-2021	Boehringer Ingelheim	Empagliflozin	Acute heart failure
Current	01-08-2021	22-03-2023	Vifor Pharma	Patiomer	Heart Failure and Hyperkalemia
Current	01-06-2022	22-03-2023	AstraZeneca	Dapaglifozin	Heart Failure
Past	01-12-2016	01-12-2019	Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.	Vericiguat	Heart Failure
Past	01-06-2018	01-11-2019	Boehringer Ingelheim	Empagliflozin	Heart Failure
Current	01-05-2019	22-03-2023	University Medical Center Hamburg _ Eppendorf	FERINJET	Iron Deficiency
Past	01-03-2017	01-11-2020	AMGEN	Omecantiv mecarbil (AMG 423)	Heart Failure
Past	01-11-2018	01-09-2020	SANOFI	Sotagliflozin/SAR439954	Types 2 Diabetes and Heart Failure
Past	01-09-2013	01-03-2015	BAYER HealthCare AG	BAY 94_8862/14564	Chronic Heart Failure
Past	01-12-2013	01-10-2016	VIFOR PHARMA	Ferric Carboxymaltose	Chronic Heart Failure with Iron deficien
Past	01-01-2011	01-08-2014	Novartis Farma	LCZ 696B 2314	Heart failure
Past	01-11-2014	01-09-2019	Novartis Farma	LCZ 696 D2301	Heart Failure
Past	01-01-2011	01-01-2014	Novartis Farma	CACZ 885M 2301 _ Canakinumab	Coronary artery disease
Past	01-11-2015	01-04-2018	Novartis Farma	LCZ 696 B2317	Heart Failure

## 1.7 Grant / Funding to organisation /institution

No interest declared

## 1.8 Close family member interest

No interest declared

## 1.9 Repurposing of a medicinal product

No interest declared

## 1.10 Any other interests or facts

Since 2022 \_ Secretary of the Heart Failure Associated Board for the 2022\_2024 term Since 2022 \_ President of the Italian Society for Heart Failure (ITAHFA) Since 2022 \_ Member of the of the Scientific Committee IRCCS San Raffaele Roma. Appointed for the 2022\_2024 term: Chairperson of the HFA Study Group on Exercise Physiology and Training Chairperson of the HFA membership Committee Chairperson of the HFA Committee Quality of Care Centres Member of the HFA Committee Advocacy Regulatory Affair Member of the HFA Committee Education Member of the HFA Committee Digital Health & Patient Care Since 2021 \_ Full Professor of Science Movement at the Department of Human Science and Promotion of Quality Life at the San Raffaele Telematic University of Rome. 2021 \_ Member of the 2022 ESC Task\_force for writing the Guidelines for the management of patients with ventricular arrhythmia and prevention of sudden death. Since 2020 \_ Member of the "Diet and nutrition Session" of the Technical Committee for Nutrition and Animal Health of the Italian Ministry of Health. 2020 \_ 2022 turn \_ Coordinator of the HFA Endorsement Committee for Higher Education of the European Society of Cardiology (ESC). 2020 \_ 2022 turn \_ HFA Patient Liaison Officer. Member of the HFA Study Group on Cachexia, Sarcopenia and Frailty. Ex\_officio member of the ESC Council on Stroke. Since 2019 \_ Fellow of the HFA (Heart Failure Association) of the European Society of Cardiology (ESC).

## 1.11 Committee for Advanced Therapies (CAT) member or alternate

Not a CAT member or alternate

## 2.1 Employment

No interest declared

## 2.2 Consultancy

No interest declared

## 2.3 Strategic advisory role

No interest declared

## 2.4 Financial interests

No interest declared

## 2.5 Principal investigator

No interest declared

## 2.6 Investigator

No interest declared

## 2.7 Grant / Funding to organisation /institution

No interest declared

## 2.8 Close family member interest

No interest declared

## 2.9 Any other interests or facts

No interest declared

---

## CONFIDENTIALITY UNDERTAKING

In view of the following definitions:

"EMA Activities" encompass any meeting (including meeting preparation and follow-up, associated discussion or any other related activity) of the European Medicines Agency's Management Board, Committees, Working Parties, Expert Groups, or any other such meeting; work as an expert on assessments; work as an expert on guidance development.

"Confidential Information" means all information, facts, data and any other matters of which I acquire knowledge, either directly or indirectly, as a result of my EMA Activities.

"Confidential Documents" mean all drafts, preparatory information, documents and any other material, together with any information contained therein, to which I have access, either directly or indirectly, as a result of my participation in EMA Activities. Furthermore, any records or notes made by me relating to Confidential Information or Confidential Documents shall be treated as Confidential Documents.

I understand that I may be invited to participate either directly or indirectly in certain EMA activities and hereby undertake:

- To treat all Confidential Information and Confidential Documents under conditions of strict confidentiality as long as the information or document has not been made public/is not in the public domain.

- Not to disclose (or authorise any other person to disclose) in any way to any third party <sup>1</sup> any Confidential Information or Confidential Document.
- Not to use (or authorise any other person to use) any Confidential Information or Confidential Document other than for the purposes of my work in connection with EMA activities.
- To dispose of Confidential Documents as confidential material as soon as I have no further use for them.
- When expressing views to indicate clearly that the views are my own if acting in my own capacity or those of the EMA, Management Board, Committee, Working Party, Expert Group or other group if acting on behalf of that group.
- Not to disclose any commercially confidential information.

This undertaking shall not be limited in time, but shall not apply to any document or information that I can reasonably prove was known to me before the date of this undertaking or which becomes public knowledge other than as a result of a breach of any of the above undertakings.

I confirm the information declared on this form is accurate and complete to the best of my knowledge and I acknowledge that my information will be stored electronically and published on the EMA website.

*1. Third party does not include employees of the National Competent Authorities who either have employment contracts that provide confidentiality obligations or are encompassed by confidentiality obligations under national legislation on professional secrecy.*

Full Name:	Maurizio Volterrani
Date:	2023-03-22

For definitions of activities etc, refer to the policy on handling of competing interests.